Given the heterogeneity of colorectal adenocarcinoma responses to anti-cancer drugs, screening of patients for P2 receptors and/or identification of mutant form of P2 receptors as well as for MRP2 expression could be beneficial in optimizing anti-cancer treatments. Here, ABCC2 is linked to colorectal adenocarcinoma.